Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin and Chemotherapy in Neoadjuvant Setting for Locally Advanced Breast Cancer
NCT01566799Phase 2Unknown
- Start
- Apr 2012
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liquid metformin (Aspargo Labs) in breast cancer (2 arms). Primary endpoint: Pathologic Complete Response at 24 weeks. Status: unknown.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01566799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01566799.